Effect of TCI188 Probiotic on Oral Health
Launched by TCI CO., LTD. · Nov 15, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a probiotic called TCI188 (Pediococcus acidilactici) on oral health, specifically targeting people with severe gum disease, also known as periodontal disease. The researchers want to see if this probiotic can help improve the condition of participants' gums and overall oral health.
To participate, you need to be at least 18 years old and have severe gum disease that is affecting multiple teeth but does not require immediate tooth removal or complicated dental work. You should not have received any gum treatment in the last year. However, if you’ve had recent dental treatments, are a smoker, pregnant, or have certain health issues, you may not be eligible to join the study. If you decide to participate, you'll be part of a research effort that could lead to new treatments for gum disease, and you'll be monitored throughout the trial to ensure your safety and well-being. The trial is currently recruiting participants, so if you're interested, it's a good idea to talk to your dentist or healthcare provider for more information.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female over 18 years old
- • Participants suffer from severe periodontal disease throughout the mouth with symptoms at third and fourth stages, do not have immediate indications for the extraction of multiple teeth or complex denture stimulation, and have not undergone periodontal planing within one year.
- Exclusion Criteria:
- • Participants have had periodontal or antimicrobial treatment within the past 6 months
- • Participants are smokers, pregnant or with systemic diseases
- • Participants had probiotic supplements or with history of adverse reactions to lactose or fermented dairy products
About Tci Co., Ltd.
TCI Co., Ltd. is a pioneering clinical trial sponsor dedicated to advancing healthcare through innovative research and development. With a strong focus on improving patient outcomes, TCI Co., Ltd. specializes in designing and managing clinical trials across various therapeutic areas. The company is committed to adhering to the highest standards of regulatory compliance and ethical practices, ensuring the integrity and reliability of its studies. By leveraging cutting-edge technologies and a team of experienced professionals, TCI Co., Ltd. strives to contribute to the development of safe and effective medical treatments, ultimately enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Taipei, Taiwan, , Taiwan
Patients applied
Trial Officials
Chin-Wei Wang
Principal Investigator
Taipei Medical University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported